Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
NCT00977977Phase 2Recruiting
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Dec 2010
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Peptides, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, cyclosporine in idiopathic membranous nephropathy (IMN), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Started Dec 2010; status: recruiting.
02
Drugs
rituximabcyclosporine
03
Conditions
idiopathic membranous nephropathy (IMN)
Beyond the preview
Go deeper on NCT00977977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00977977.